Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

The medicines regulator has issued a warning to NHS health staff about a small increased risk of a rare condition affecting ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

The GSK RSV vaccine Arexvy is not currently available on the NHS but may be available privately in the UK. Symptoms of Guillain-Barre syndrome can include tingling, numbness or pins and needles in ...

The arrangement will run for three years in the first instance and, according to GSK, also “supports potential future co-development and commercialisation of Arexvy […] for adults 60 years and ...

In its update posted this morning, GSK revealed that sales of its Arexvy vaccine came in at £1.24 billion ($1.57 billion) in 2023, including £529 million ($671 million) from the fourth quarter.

The U.S. Centers for Disease Control and Prevention (CDC) has accepted recommendations from an advisory panel that endorsed ...

A new study from the University of Oxford has revealed a surprising benefit of the respiratory syncytial virus (RSV) vaccine: ...

Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...